In contrast, antitumor necrosis factor therapy using etanercept or infliximab has compiled an unimpressive record overall for PMR in case reports and pilot studies.
“At present, I think there is no role for antitumor necrosis factor therapy in PMR,” he said.
Disclosures: Dr. Cimmino disclosed having received research grants from numerous pharmaceutical companies, including Roche, Schering Plough, Abbott, and Pfizer.
